« Back

Sarepta Therapeutics Announces Presentations at the 19th International Congress of the World Muscle Society

10/08/14 8:31 AM EDT

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 8, 2014-- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a developer of innovative RNA-based therapeutics, today announced that it will give one oral presentation and two poster presentations on data from its ongoing Phase II and preclinical trials evaluating exon-skipping therapies for the treatment of Duchenne muscular dystrophy (DMD) at the International Congress of the World Muscle Society (WMS), being held from October 7-11, 2014, in Berlin, Germany. The oral presentation will include additional detail about the 144-week, 6-minute walk test (6MWT) and safety data from the Phase IIb study of eteplirsen, as well as other information including 144-week pulmonary function test results and information on individual MIP and MEP results.

Details of Sarepta’s presentations at WMS are as follows:

Oral Presentation :

Session Title:     Treatment approaches in the clinic
Title:

Eteplirsen in Duchenne Muscular Dystrophy (DMD): 3 year update on Six-Minute-
Walk Test (6MWT) and Safety

Presenter: Jerry R. Mendell, M.D., of Nationwide Children’s Hospital
Date & Time: Saturday, Oct. 11, 9:00-10:30 a.m. GMT+2 (3:00-4:30 a.m. EST)
Location Langenbeck-Virchow-Haus
 

Poster Presentations:

Session Title:

    DMD 2 Therapeutic Evaluations and Approaches
Title:

Safety and pharmacokinetic profile of eteplirsen, SRP-4045, and SRP-4053, three
phosphorodiamidate morpholino oligomers (PMOs) for the treatment of patients with
Duchenne muscular dystrophy (DMD)

Date & Time: Wednesday, Oct. 8, 4:00-5:30 p.m. GMT+2 (10:00 – 11:30 a.m. EST)
Location Thaersaal/Humboldt Graduate School
 
Session Title: DMD 2 Therapeutic Evaluations and Approaches
Title:

Pulmonary function is stable through 120 weeks in patients with Duchenne muscular
dystrophy (DMD) treated with exon-skipping drug eteplirsen in phase 2b study

Date & Time: Wednesday, Oct. 8, 4:00-5:30 p.m. GMT+2 (10:00 – 11:30 a.m. EST)
Location Thaersaal/Humboldt Graduate School
 

The oral presentation will be archived under the events and presentations section of the Sarepta Therapeutics website at www.sarepta.com following the presentation for 90 days.

About Sarepta Therapeutics

Sarepta Therapeutics is focused on developing first-in-class RNA-based therapeutics to improve and save the lives of people affected by serious and life-threatening rare and infectious diseases. The Company's diverse pipeline includes its lead program eteplirsen, for Duchenne muscular dystrophy, as well as potential treatments for some of the world's most lethal infectious diseases. Sarepta aims to build a leading, independent biotech company dedicated to translating its RNA-based science into transformational therapeutics for patients who face significant unmet medical needs. For more information, please visit us at www.sarepta.com.

Source: Sarepta Therapeutics, Inc.

Sarepta Investor Contact:
Stephanie Ascher, 212-362-1200
stephanie@sternir.com
or
Sarepta Media Contact:
Tony Plohoros, 908-591-2839
tplohoros@6degreespr.com

 

This section of our website may contain dated or archived information which should not be considered current and may no longer be accurate. For current information, you are encouraged to review our most recent official corporate documents on file with the U.S. Securities and Exchange Commission.